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Opinion statement
Isolated limb perfusion (ILP) with chemotherapy alone has uniformly failed in the
treatment of irresectable extremity soft tissue sarcomas. The addition of tumor necrosis
factor-alpha (TNF-a) to this treatment approach contributed to a major step forward in
the treatment of locally advanced extremity soft tissue sarcoma (STS). High response
rates and limb salvage rates have been reported in multicenter trials, which combined
ILP with TNF-a plus melphalan, which resulted in the approval of TNF-a for this indi-
cation in Europe in 1998. Subsequently a series of confirmatory single institution reports
on the efficacy of the procedure have now been published. TNF-a has an early and a late
effect; it enhances tumor-selective drug uptake during the perfusion and plays an
essential role in the subsequent selective destruction of the tumor vasculature. These
effects result in a high response rate in high-grade soft tissue sarcomas. This induction
therapy thus allows for resection of tumor remnants some 3 months after ILP and thus
avoidance of limb amputation. TNF-a-based ILP is a well-established treatment to avoid
amputations. It represents an important example of tumor vasculatory-modulating
combination therapy and should be offered in large volume tertiary referral centers.
Introduction
Patients with a large, high-grade soft tissue sarcoma
(STS) of the extremities have a high risk for local and
systemic recurrences. The local situation in the limb
may require extensive and mutilating surgery followed
by radiotherapy. Several studies suggested that
amputation of the limb did not result in an improved
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survival. The tendency to perform more limb-
preserving surgery has led to the exploration of isolated
limb perfusion (ILP) as a procedure enabling limb
salvage surgery in cases of primarily STS, requiring
mutilating surgery or even amputation of the limb. The
technique of ILP achieves regional drug concentrations
15–25 times higher than systemic administration and
is without systemic side effects [1,2]. Isolation of the
limb is achieved by clamping and cannulation of the
major artery and vein, connection to an oxygenated
extracorporeal circuit, ligation of collateral vessels, and
application of a tourniquet (Fig. 1). Because of its
efficacy and low regional toxicity profile, melphalan
(L-phenyl-alaninemustard) is the standard drug and is
most commonly used at a dose range of 10 mg/L (for
the leg) to 13 mg/L (for the arm) [3]. ILP procedures
are performed under mild hyperthermic conditions
(38.5–40C) as it has become clear that hyperthermia
can increase the drug uptake in the cells, but that true
hyperthermia (>41C) is associated with increased
local toxicity. Tissue temperatures are monitored and
radiolabeled serum albumen or erythrocytes are in-
jected into the perfusate to detect leakage into the
systemic circulation by a precordial scintillation probe.
Leakage monitoring is mandatory especially now that
TNF-a is used, since leakage of TNF-a can theoretically
lead to significant toxicity such as hypotension and
septic shock-like syndrome. After 1–1.5 hours of per-
fusion, the limb is rinsed with an electrolyte solution,
cannulas are removed, and the vessels are repaired.
Acute tissue reactions after perfusion are classified in a
5-grade system according to Wieberdink et al. [4] (I) no
reaction; (II) slight erythema and/or edema; (III)
considerable erythema and/or edema with some blis-
tering; (IV) extensive epidermolysis and/or obvious
damage to the deep tissues causing definite functional
disturbances; threatening or manifest compartmental
syndrome; (V) reaction which may necessitate ampu-
tation. The advent of TNF-a has greatly expanded the
successful application of ILP, and we will discuss these
relatively recent developments.
Failure of ILP with chemotherapy alone
• Achieving limb salvage has become a key element in the management
of locally advanced soft tissue sarcomas (STS) of the extremities,
because there is ample evidence that amputations do not improve
survival rates in patients with large (>5 cm) deep-seated high-grade
sarcomas [5,6]. Locally advanced STS are often large at the time of
diagnosis, and treatment options may consist of an amputation or a
limb sparing extensive surgical procedure followed by radiation
therapy which may cause severe disability of the limb. The insight that
limb-preserving surgery is equal to amputation in terms of overall
survival [7,8] greatly enhanced the interest in neoadjuvant treatment
options that could reduce the size of the tumors and hence make
function-preserving surgery possible. The possible role of induction
chemotherapy was recently studied by the MD Anderson Cancer
Center, but although a tumor response was observed in 43% of these
patients, the therapy could only reduce the extent of operation in 13%
and no scheduled amputation could be prevented [9]. Preoperative
radiotherapy has not been studied as an induction therapy in patients
with primary irresectable extremity STS. It has been shown to be as
effective as postoperative radiotherapy in STS patients, but at the cost
of higher wound complication rates [10]. Literature suggests that
combined neoadjuvant chemoradiotherapy with limb salvage surgery
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Figure 1. Isolated limb perfusion circuit
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is an option for treating patients with deep STS of the extremity, but
up to now, this treatment option remains investigational and results
from large studies have to be awaited [11–13]. ILP has the ability to
deliver the highest doses of (bio)chemotherapy to the affected limb
and is thus a treatment modality that can be effective in the neoad-
juvant setting. In contrast to the efficacy of melphalan-based ILP for
small intransit melanoma metastases, however, results of ILP with
melphalan, doxorubicin, or any other drug for large STS have been
very disappointing. Presumably this is mainly due to impaired drug
uptake in large tumors. For treating advanced STS, ILP with chemo-
therapy alone was abandoned after studies in the 1970s and 1980s
[14–17]. These findings were reinforced by a study of ILP with
doxorubicin, where Feig and coworkers reported a dismal 0%
response rate and an amputation rate of 75% [18], in line with our
experience.
Success of TNF-a plus chemotherapy in ILP
• The introduction of TNF-a in the ILP setting was pioneered by Lejeune
et al. [19]. In 13 melanoma patients and four locally advanced STS
cases impressive and very rapid responses were observed. This obser-
vation was followed by multicenter trials in patients with locally
advanced STS [14,16,18,20] and melanoma [21–23]. Table 1
summarizes all literature reports on TNF-a-based ILP in STS patients.
In the STS trials, TNF-a-based ILP was established as a highly effective
new method of induction biochemotherapy for extremity STS with a
20%–30% complete remission (CR) rate and 50% partial remission
(PR) rate [20,41,26,28]. On the basis of our multicenter trials TNF-a
was approved and registered in Europe for sarcoma treatment in 1998
[28]. In four studies over a 10-year-period, the European TNF/ILP
assessment group evaluated 270 ILPs in 246 patients with irresectable
STS. All cases were reviewed by an independent review committee and
compared with a population based Scandinavian STS database of
patients receiving conventional treatment (often an amputation).
There were 246 patients with local and very advanced disease. Primary
sarcomas occurred in 55% of patients, local recurrent sarcomas in
45%, multifocal primary or multiple local recurrences in 22%, and
overt concurrent metastatic disease in 15%. Tumors >10 cm were
found in 46% of patients, and tumors were a high grade with 95%
showing grade II–III tumors. In 76% of cases a delayed marginal
resection of the tumor remnant was usually performed 2–4 months
after ILP. Major responses were seen in 56.5%–82.6% of patients, after
which resection of the sarcoma became possible in most cases. Limb
salvage was achieved in 74%–87% in these four studies. In 71% of the
196 patients who had been classified by the independent review
committee, 87% were considered cases that could only have been
managed by amputation and 13% by functionally debilitating resec-
tion plus radiotherapy. A matched control study with cases from the
Scandinavian STS Databank showed that TNF-a had no negative effect
on survival (P = 0.96). In this high-risk population overall survival
was around 50% at 5 years [28]. It was concluded that ILP with TNF-a
and melphalan represents a new and successful option in the man-
agement of irresectable locally advanced extremity STS [28]. The
approval in Europe of TNF-a for its use in the ILP setting for locally
advanced STS has led to training and activation of over 40 centers in
Europe to provide one or more referral programs in each country.
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These programs are running well and experiences are rather uniform
and in line with the initial trials as is indicated by the list of single
center studies that have been published over the years (Table 1)
Unfortunately TNF-a is not clinically available in North America
because the patent and licensing rights of TNF-a are in the hands of a
different company and thus the registration file has not been pre-
sented to the FDA.
Vasculotoxic mechanism of TNF-a plus chemotherapy
• As TNF-a targets the tumor vasculature, which is a common denom-
inator in all these tumor types, the use of TNF-a is very attractive and it
explains its efficacy in combination with chemotherapy across these
numerous histologies. The selective destructive effects of TNF-a-based
ILP on tumor-associated vessels are illustrated in the pre- and post-
perfusion angiographies in Fig. 2. In magnetic resonance spectrometry
studies, we have shown that shutdown of the tumor is virtually
Table 1. Study reports of TNF-based ILP for irresectable soft tissue sarcomas
Drugs #
Pts
CR
(%)
PR
(%)
Limb salvage
(%)
Year Author
TNF + Melphalan* 8 100a 0 64 1993 Hill et al. [24]
TNF + IFN + Melphalan 55 18a 64a 84 1996 Eggermont et al. [20]
36b 51b
TNF + Melphalan 10 70a 20a 89 1996 Santinami et al. [25]
TNF ± IFN + Melphalan 186 18a 57a 82 1996 Eggermont et al. [26]
29b 53b
TNF ± IFN + Melphalan 35 37b 54b 85 1997 Gutman et al. [27]
TNF ± IFN + Melphalan 246 28c 48c 76 1999 Eggermont et al. [28]
196 17c 48c 71d
TNF + Doxorubicin 20 26e 64e 85 1999 Rossi et al. [29]
TNF ± IFN + Melphalan 22 18b 64b 77 2000 Lejeune et al. [30]
TNF ± IFN + Melphalan 55 NS NS 84 2001 Hohenberger et al. [31]
TNF ± IFN + Melphalan 49 8b 55b 58 2003 Noordap et al. [32]
TNF ± IFN + Melphalanh 48 38b 31b 85 2005 Gru¨nhagen et al. [33]
TNF + Melphalang,h 72 49 17 84 2005 Bonvalot et al. [34]
35 22
TNF + Doxorubicinh 21 5a 57a 71 2005 Rossi et al. [35]
55e 35e
TNF ± IFN + Melphalan 217 18a 51a 75 2006 Gru¨nhagen et al. [36]
26b l49b
TNF + Doxorubicin/Melphalanh 51 41a 55a 82 2007 Pennacchioli et al. [37]
TNF ± IFN + Melphalan 73 25a 69a 616 2007 van Ginkel et al. [38]
TNF + Melphalan 100 30 48 88 2007 Bedard et al. [39]
TNF + Melphalan 16 20 33 75 2007 Hayes [40]
#Pts—number of patients, CR—Complete response; PR—Partial response; Ref#—reference number, TNF—Tumour Necrosis Factor,
IFN—Interferon gamma. *—low dose (<4 mg for leg-ILP, <3 mg for arm-LIP), NS—not stated
aObjective Clinical Response Rate By WHO criteria
bCR: clinical CR or 100% necrosis; PR: clinical PR or >50%–99% necrosis
cCR only recognized by EMEA (European Medicine Evaluation Agency) when histopathology showed 100% necrosis
dIndependent committee recognized 196 patients as pure amputation candidates
eNo clinical response data; CR: >90% necrosis; PR: radiological and/or histopathological >50% necrosis.
fOverall 10 years’ limb salvage rate
gDifferent scoring system: upper panel: CR/PR: loss of vasculature on Ultrasound/MRI; lower panel CR: >90% necrosis on histopathology
hlow dose (<4 mg for leg-ILP, <3 mg for arm-ILP)
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complete within 16 hours after the perfusion, confirming the likeli-
hood of TNF-a-mediated effects on the vasculature of the tumor [42].
At the histopathological level, it has been demonstrated that TNF-a
induces microvascular damage through loss of endothelial cohesion
[43]. This leads to intravascular effects, such as thrombocyte aggre-
gation and erythrostasis, with hemorrhagic necrosis as the result. The
vascular destruction is important in the early and late stages after ILP
[44–46]. Moreover, besides the small direct cytotoxic effect of TNF-a
and the far more important vasculotoxic mechanism, speculations
exist on a third role, namely the ability of TNF-a to cause an imme-
diate drop in interstitial pressure within the tumor [47].
TNF-a enhances selective drug uptake in tumors
• We have recently demonstrated that the addition of high-dose TNF-a
to the perfusate results in a 4–6 fold increased uptake by the tumor of
the cytostatic drugs melphalan and doxorubicin [48,49]. Importantly
this uptake was tumor specific and no increased uptake was noted in
the normal tissues, thus emphasizing the selective action of TNF-a on
the tumor vasculature. The more vascular the tumor was, the better the
synergistic effect was between TNF-a and the chemotherapeutic agent
[50]. We also demonstrated that 10 lg of TNF-a (a 5-fold reduction of
the ‘standard dose of 50 lg’) was the minimum threshold dose for
activity of TNF-a in our rat tumor extremity perfusion model. At 2 lg
doses of TNF-a all effects were lost [51]. The results from our tumor
models predict a minimum threshold activity for 1 mg TNF-a in the
clinical situation and we advise not to go below that dose. We dem-
onstrated that TNF-a and melphalan when combined with the effects
of hyperthermia above 40C leads to amputations because of normal
tissue damage, and we advise against its use in the clinic [51]. Fur-
thermore we showed that actinomycin D, commonly used in the
Figure 2. Selective eradication of tumor vasculature by TNF-based ILP (left pre-ILP; right post ILP)
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clinical setting, leads to idiosyncratic toxicity in our models of both
tumor and normal tissues, resulting in limb amputation in all cases.
We strongly advise not to use TNF-a in combination with actinomycin
D in the clinical setting [52].
Reports on all STS patients
• Many single center studies of TNF-a plus melphalan have been reported
over the past years that showed similar response and limb salvage rates
(Table 1). Studies have reported overall experience in STS patients or of
special categories (see below) of STS patients. The single center reports
on overall STS populations showed that response rates varied from 53%
to 91% and limb salvage rates from 58% to 89%. Two reports on the
combination of TNF-a with doxorubicin show very similar response
rates of 62%–90% and limb salvage rates of 71%–85%, with more
regional toxicity after doxorubicin compared with melphalan [29,35].
We therefore consider melphalan to be the drug of choice.
• Another aspect that has been studied in overall populations is whether
high doses of TNF-a (eg, 3–4 mg) are necessary or whether lower
doses (eg, 1 mg) suffice. An early clinical report by Hill and coworkers
suggested that low doses of TNF-a (i.e. up to 1 mg) were sufficient
because in eight STS patients eight complete responses were observed
[34]. The small study size, the concomitant use of high doses of
corticosteroids, and the fact that a different type of TNF-a was used,
however, meant that definitive conclusions were not possible. Defin-
itive conclusions came from the Italian studies of 1 mg TNF-a in
combination with doxorubicin [29,35], the French randomized phase
II trial in 100 patients on four TNF-a doses (0.5, 1.0, 2.0, and 4.0 mg)
[34], and our analysis of 240 ILPs where the TNF-a doses varied from
1.0, 2.0, 3.0, and 4.0 mg. All these studies seem to indicate that TNF-a
doses of 1 mg (for the arm) and 1–2 mg (for the leg) are sufficient
[33]. Recently, Bedard et al. [39] confirmed their previous findings
[34] of the success of low-dose TNF-a in a prospective study of 100
patients with locally advanced STS treated by ILP and 1 mg TNF-a/
melphalan. This is consistent with findings from our laboratory,
which indicate that doses of 1 mg TNF-a were sufficient, but further
dose reduction resulted in complete loss of activity [51].
Reports on special patient categories
Patients with overt metastatic disease
• Patients who have overt metastatic disease and a limb-threatening
tumor are a special category whereby tumor control can be relatively
easily achieved, and amputation avoided, by a palliative TNF-a-based
ILP. In nine such cases, a 77% response rate and 89% limb salvage rate
was reported [53], and we observed a 84% response rate and 97%
limb salvage rate in 37 cases [54]. This demonstrates that TNF-a-based
ILP is an extremely attractive option in these patients.
Patients with multiple tumors in the extremity
• TNF-a-based ILP is the ideal alternative to amputation in patients with
multifocal primary tumors, who are difficult to treat, such as Kaposi
sarcomas [55], multiple lymphangio-sarcomas (also known as
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Steward Treves Syndrome) [56], or those with multiple primaries of
various histologies or multiple recurrences after prior surgery [57].
Remarkably good results have been reported, and we observed a 87%
response rate and a 80% limb salvage rate after 16 TNF-a-based ILPs
were performed in 10 patients with Steward Treves Syndrome. In our
experience, after 64 ILPs we observed a 77% response rate and 82%
limb salvage rate in patients with multiple tumors. These results
indicate that TNF-a-based ILP is very effective in this patient
population.
Patients with recurrent tumors in an irradiated field
• We performed 29 ILPs in 26 patients with recurrent tumors in an
irradiated field. In contrast to the belief that such tumors are
unlikely to respond, we observed a 70% response rate and 65%
limb salvage rate, indicating that in this very difficult patient
category a TNF-a -based ILP approach is an attractive treatment
option [58].
Patients with desmoids
• Patients with desmoid tumors and aggressive fibromatosis often
present with recurrent disease, which is very difficult to treat surgi-
cally with or without radiotherapy. Lev-Lelouche et al. and our group
report very similar results in 6 and 12 such cases, respectively.
Response rates were 83% and 75%, respectively, and limb salvage
rates were 100% in both reports, demonstrating the utility of this
procedure [59,60].
Elderly patients >75 years old
• An important result was demonstrated by the report on the Rotterdam
experience of patients older than 75 years with limb -threatening
tumors treated with 50 TNF-a-based ILPs [61]. Results were very
favorable in the 34 perfusions for limb-threatening sarcomas; a 38%
CR and a 38% PR rate, achieving limb salvage in 76% of the patients,
as well as in 16 perfusions for bulky melanoma intransit metastases
resulting in a 75% CR and 25% PR rate, were observed. The procedure
was proven safe in the elderly with limb salvage, which is of over-
riding importance in these patients as an amputation can abolish
independency of the life [61]. In the present era of leakage-free ILPs,
TNF-a-based ILPs are associated with very little toxicity problems. We
have separately reported on the absence of toxicity in patients without
leakage [33,62]. In the rare case of systemic leakage of TNF-a man-
agement is relatively easy and requests the use of ample hydration and
non-steroid anti-inflammatory drugs, and toxicity can be minimal
[63]. In our total experience of >450 ILP procedures, no toxic shock-
like syndrome has occurred using this regimen. Moreover, TNF-a-based
ILPs are not associated with a higher regional toxicity compared
with melphalan-based ILPs, and have less regional toxicity than
doxorubicin-based ILPs [64].
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New vasoactive drugs
Histamine
• Because of the potential toxicity of TNF-a, alternative vasoactive drugs
were investigated in our center. Histamine (Hi) is an inflammatory
mediator that is formed and stored mainly in the granules of mast
cells and basophils. It has also been identified in cells in regenerating
or rapidly growing tissues. Its effect on fine vessels is to cause edema
by increasing the flow of lump and lymph proteins into the extra-
cellular space and also by promoting the formation of gaps between
endothelial cells [65]. This effect could potentially be used to increase
drug concentrations in tumor tissues. We used a sarcoma-bearing rat
ILP model to assess the effects of Hi, melphalan, and the combination
[66]. The antitumor effect of the combination Hi and melphalan was
synergistic. The strong effect of Hi-based-ILP with melphalan was
explained by three mechanisms: direct cytotoxicity to the tumor cells,
direct cytotoxicity to the tumor-associated vasculature, and indirect
effect through Hi-mediated increased melphalan concentration in the
tumor. There are several theoretical advantages in using Hi instead of
TNF-a. In brief; it has been hypothesized that ILP with Hi would likely
enhance drug uptake more quickly and effectively than ILP with TNF-
a, and Hi is a potentially safer drug than TNF-a in case of leakage into
the systemic circulation during ILP [66].
Interleukin-2
• Interleukin-2 (IL-2) is another candidate to enhance tissue uptake of
cytotoxic agents. IL-2 is a mediator of immune cell activation with
some antitumor activity. IL-2 causes vascular leakage and edema and
for this reason we examined the antitumor activity of a combined
treatment with IL-2 and melphalan in an experimental ILP setting
[67]. ILPs were performed in soft tissue sarcoma-bearing rats. ILP with
either IL-2 or melphalan alone has no antitumor effect, but the
combination of IL-2 and melphalan resulted in a strong synergistic
tumor response, without any local or systemic toxicity. IL-2 signifi-
cantly enhanced melphalan uptake in tumor tissue without signs of
significant vascular damage to account for this observation. Obser-
vations indicated a potentially important role for macrophages as an
explanation for the strong synergistic effect of IL-2. In systemic
immunotherapy, the combination of IL-2 and Hi has been used for
solid tumor treatment based on immunomodulatory effects. Also
because of the success of IL-2 in ILP and the earlier-mentioned success
of Hi in ILP model, we studied if the two drugs combined with
melphalan could further improve response rates in an experimental
ILP. In a sarcoma-bearing rat ILP model the effects were assessed [68].
A negative synergistic effect was found between IL-2 and Hi in a
regional setting.
Conclusions and future directions
• ILP methodology provides us an excellent tool in the clinic to obtain
local control and avoid amputations of limbs in patients with limb-
threatening tumors. This has been largely achieved by the success of
the antivascular TNF-based biochemotherapy in this setting. TNF-a,
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for the first time, has brought us an effective treatment against large,
bulky tumors. TNF-a-based ILP is a very successful treatment option to
achieve limb salvage in the management of advanced disease, multi-
ple or drug-resistant extremity tumors. TNF-a-based ILPs are now
performed in over 40 cancer centers in Europe with referral programs
for limb salvage. Provision should be made to make TNF-a available
in North America. TNF-a-based antivascular therapy of cancer is here
to stay and its potential needs to be studied further, including its use
in the systemic setting. In the field of isolated-perfusion newly dis-
covered vasoactive drugs await evaluation in clinical trials [69].
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